Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jan Basile

Internal Medicine Charleston, SC Medical Doctor

NPI 1841394475 CMS profile 174640

109 Bee St, Charleston, SC 29401

Open in the dashboard

General payments

$277,935

338 records reported · program years 2019–2025

Research payments

$19,658

Paid to them · 21 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jan Basile of Charleston, SC is reported in the CMS Open Payments database as having received $277,935 across 338 general payments and $19,658 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $41,247 39
2025 Research $1,456 8
2024 General $99,472 113
2023 General $43,103 53
2022 General $54,871 74
2021 General $21,209 40
2021 Research $1,838 2
2020 Research $2,625 4
2019 General $18,034 19
2019 Research $13,739 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jan Basile
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jan Basile were reported at $41,247. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jan Basile Internal Medicine median Middle half National median
2019 $18,034 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $21,209 $135 $37–$521 $132
2022 $54,871 $141 $42–$496 $149
2023 $43,103 $149 $45–$519 $160
2024 $99,472 $154 $47–$537 $164
2025 $41,247 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eli Lilly and Company $147,608 164 payments
  2. Novo Nordisk Inc $43,581 31 payments
  3. Medtronic, Inc. $27,602 41 payments
  4. Corcept Therapeutics $22,069 34 payments
  5. Blue Earth Diagnostics Limited $13,300 1 payment
  6. Idorsia Pharmaceuticals US Inc $5,411 5 payments
  7. Janssen Scientific Affairs, LLC $5,087 2 payments
  8. Relypsa, Inc. $4,973 9 payments
  9. AstraZeneca Pharmaceuticals LP $4,364 7 payments
  10. Recor Medical Inc $2,465 3 payments
  11. Other $1,475 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $203,855 113 payments
  2. Travel and Lodging $43,907 85 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $22,477 7 payments
  4. Food and Beverage $7,433 127 payments
  5. Education $263 6 payments
Products named General payments · program years 2019–2025
  1. Korlym $21,825 30 payments
  2. POSLUMA $13,300 1 payment
  3. TRULICITY $12,621 11 payments
  4. Ozempic $11,149 6 payments
  5. Tryvio $5,411 5 payments
  6. Veltassa $4,973 9 payments
  7. Paradise Ultrasound Renal Denervation System $2,465 3 payments
  8. SYMPLICITY G3 $2,012 20 payments
  9. Repatha $476 3 payments
  10. MOUNJARO $137 3 payments
  11. Other $577 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $8,313 9 payments
  2. Eli Lilly and Company $8,052 2 payments
  3. Medtronic, Inc. $1,838 2 payments
  4. Corcept Therapeutics $1,456 8 payments

Records

359 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record